The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
Animals
Cell Transformation, Neoplastic
/ genetics
Disease Models, Animal
F-Box-WD Repeat-Containing Protein 7
/ genetics
Gene Expression Regulation, Neoplastic
Humans
Mutation
Neoplasms
/ genetics
Phosphorylation
/ genetics
Prognosis
Proteasome Endopeptidase Complex
/ metabolism
Protein Interaction Maps
/ genetics
Proteolysis
Receptors, Notch
/ genetics
Ubiquitin
/ metabolism
E3 ligase
FBXW7
NOTCH
SCF
cancer
diagnostic markers
mutation
therapeutics
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
21
02
2021
received:
12
08
2020
accepted:
01
03
2021
pubmed:
7
4
2021
medline:
5
2
2022
entrez:
6
4
2021
Statut:
ppublish
Résumé
Ubiquitin ligases or E3 ligases are well programmed to regulate molecular interactions that operate at a post-translational level. Skp, Cullin, F-box containing complex (or SCF complex) is a multidomain E3 ligase known to mediate the degradation of a wide range of proteins through the proteasomal pathway. The three-dimensional domain architecture of SCF family proteins suggests that it operates through a novel and adaptable "super-enzymatic" process that might respond to targeted therapeutic modalities in cancer. Several F-box containing proteins have been characterized either as tumor suppressors (FBXW8, FBXL3, FBXW8, FBXL3, FBXO1, FBXO4, and FBXO18) or as oncogenes (FBXO5, FBXO9, and SKP2). Besides, F-box members like βTrcP1 and βTrcP2, the ones with context-dependent functionality, have also been studied and reported. FBXW7 is a well-studied F-box protein and is a tumor suppressor. FBXW7 regulates the activity of a range of substrates, such as c-Myc, cyclin E, mTOR, c-Jun, NOTCH, myeloid cell leukemia sequence-1 (MCL1), AURKA, NOTCH through the well-known ubiquitin-proteasome system (UPS)-mediated degradation pathway. NOTCH signaling is a primitive pathway that plays a crucial role in maintaining normal tissue homeostasis. FBXW7 regulates NOTCH protein activity by controlling its half-life, thereby maintaining optimum protein levels in tissue. However, aberrations in the FBXW7 or NOTCH expression levels can lead to poor prognosis and detrimental outcomes in patients. Therefore, the FBXW7-NOTCH axis has been a subject of intense study and research over the years, especially around the interactome's role in driving cancer development and progression. Several studies have reported the effect of FBXW7 and NOTCH mutations on normal tissue behavior. The current review attempts to critically analyze these mutations prognostic value in a wide range of tumors. Furthermore, the review summarizes the recent findings pertaining to the FBXW7 and NOTCH interactome and its involvement in phosphorylation-related events, cell cycle, proliferation, apoptosis, and metastasis. The review concludes by positioning FBXW7 as an effective diagnostic marker in tumors and by listing out recent advancements made in cancer therapeutics in identifying protocols targeting the FBXW7-NOTCH aberrations in tumors.
Sections du résumé
BACKGROUND
Ubiquitin ligases or E3 ligases are well programmed to regulate molecular interactions that operate at a post-translational level. Skp, Cullin, F-box containing complex (or SCF complex) is a multidomain E3 ligase known to mediate the degradation of a wide range of proteins through the proteasomal pathway. The three-dimensional domain architecture of SCF family proteins suggests that it operates through a novel and adaptable "super-enzymatic" process that might respond to targeted therapeutic modalities in cancer.
RECENT FINDINGS
Several F-box containing proteins have been characterized either as tumor suppressors (FBXW8, FBXL3, FBXW8, FBXL3, FBXO1, FBXO4, and FBXO18) or as oncogenes (FBXO5, FBXO9, and SKP2). Besides, F-box members like βTrcP1 and βTrcP2, the ones with context-dependent functionality, have also been studied and reported. FBXW7 is a well-studied F-box protein and is a tumor suppressor. FBXW7 regulates the activity of a range of substrates, such as c-Myc, cyclin E, mTOR, c-Jun, NOTCH, myeloid cell leukemia sequence-1 (MCL1), AURKA, NOTCH through the well-known ubiquitin-proteasome system (UPS)-mediated degradation pathway. NOTCH signaling is a primitive pathway that plays a crucial role in maintaining normal tissue homeostasis. FBXW7 regulates NOTCH protein activity by controlling its half-life, thereby maintaining optimum protein levels in tissue. However, aberrations in the FBXW7 or NOTCH expression levels can lead to poor prognosis and detrimental outcomes in patients. Therefore, the FBXW7-NOTCH axis has been a subject of intense study and research over the years, especially around the interactome's role in driving cancer development and progression. Several studies have reported the effect of FBXW7 and NOTCH mutations on normal tissue behavior. The current review attempts to critically analyze these mutations prognostic value in a wide range of tumors. Furthermore, the review summarizes the recent findings pertaining to the FBXW7 and NOTCH interactome and its involvement in phosphorylation-related events, cell cycle, proliferation, apoptosis, and metastasis.
CONCLUSION
The review concludes by positioning FBXW7 as an effective diagnostic marker in tumors and by listing out recent advancements made in cancer therapeutics in identifying protocols targeting the FBXW7-NOTCH aberrations in tumors.
Identifiants
pubmed: 33822486
doi: 10.1002/cnr2.1369
pmc: PMC8388169
doi:
Substances chimiques
F-Box-WD Repeat-Containing Protein 7
0
FBXW7 protein, human
0
Receptors, Notch
0
Ubiquitin
0
Proteasome Endopeptidase Complex
EC 3.4.25.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1369Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Rev Bras Ortop. 2014 Oct 27;49(6):555-64
pubmed: 26229862
Cancer Rep (Hoboken). 2021 Aug;4(4):e1369
pubmed: 33822486
Genes (Basel). 2019 Nov 22;10(12):
pubmed: 31766724
Front Cell Dev Biol. 2017 Jan 18;4:151
pubmed: 28149836
Dis Markers. 2010;28(6):353-60
pubmed: 20683149
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):6731-6
pubmed: 27247421
Gastric Cancer. 2019 Nov;22(6):1100-1108
pubmed: 30854619
Mol Cancer Ther. 2012 May;11(5):1155-65
pubmed: 22389469
Leukemia. 2010 Dec;24(12):2023-31
pubmed: 20861920
Mol Cell. 2012 Jun 29;46(6):771-83
pubmed: 22608923
BMC Cancer. 2016 May 26;16:335
pubmed: 27229929
Curr Cancer Drug Targets. 2011 Mar;11(3):347-56
pubmed: 21247385
J Agric Food Chem. 2011 Jun 22;59(12):6765-75
pubmed: 21598989
Exp Cell Res. 2011 Oct 15;317(17):2438-46
pubmed: 21820430
Curr Drug Targets. 2013 Sep;14(10):1150-6
pubmed: 23834147
BMC Biol. 2010 Dec 23;8:153
pubmed: 21182779
Oncotarget. 2014 Jun 15;5(11):3444-54
pubmed: 24899509
Neurosci Lett. 2015 Jul 23;600:6-11
pubmed: 26033182
Med J Armed Forces India. 1998 Jan;54(1):76-78
pubmed: 28775426
EMBO Mol Med. 2014 Jan;6(1):99-119
pubmed: 24357640
Crit Rev Oncog. 2013;18(1-2):43-73
pubmed: 23237552
PLoS One. 2012;7(10):e46567
pubmed: 23056346
J Oral Maxillofac Pathol. 2014 May;18(2):286-90
pubmed: 25328314
Cancer Cell Int. 2016 Nov 15;16:86
pubmed: 27895530
Biochem Biophys Res Commun. 2014 Nov 7;454(1):71-7
pubmed: 25445601
J Clin Invest. 2015 Feb;125(2):621-35
pubmed: 25555218
Oncogene. 2010 May 20;29(20):2950-61
pubmed: 20208556
Cancer Cell. 2019 Sep 16;36(3):319-336.e7
pubmed: 31526760
J Exp Med. 2007 Aug 6;204(8):1813-24
pubmed: 17646409
Oncotarget. 2017 Aug 10;8(43):74479-74493
pubmed: 29088801
Blood. 2008 May 1;111(9):4690-9
pubmed: 18305219
Oncogene. 2008 Oct 16;27(47):6164-74
pubmed: 18641686
Cell Death Dis. 2018 Aug 29;9(9):883
pubmed: 30158600
Toxicol Pathol. 2007 Jun;35(4):495-516
pubmed: 17562483
Memo. 2017;10(4):220-223
pubmed: 29250200
Biochem Biophys Res Commun. 2008 Apr 18;368(4):1007-13
pubmed: 18275844
Biosci Rep. 2017 Jun 21;37(3):
pubmed: 28507201
J Invest Dermatol. 2012 Dec;132(12):2810-7
pubmed: 22718117
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90
pubmed: 15150404
Br J Haematol. 2012 Sep;158(5):626-34
pubmed: 22775572
Aging (Albany NY). 2016 Apr;8(4):603-19
pubmed: 27019364
Leukemia. 2015 Jun;29(6):1301-11
pubmed: 25655195
J Biol Chem. 2003 Nov 21;278(47):46862-8
pubmed: 12954644
Cancer Metastasis Rev. 2012 Jun;31(1-2):75-87
pubmed: 22124735
Front Immunol. 2018 Aug 20;9:1718
pubmed: 30967879
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):167-174
pubmed: 30077638
Science. 2012 Aug 31;337(6098):1094-7
pubmed: 22798407
PLoS One. 2012;7(7):e41116
pubmed: 22848434
Neural Dev. 2012 May 03;7:15
pubmed: 22554084
Semin Cancer Biol. 2020 Dec;67(Pt 2):1-15
pubmed: 32113998
Int J Mol Sci. 2019 Oct 23;20(21):
pubmed: 31652668
BMC Gastroenterol. 2017 May 2;17(1):60
pubmed: 28464881
Bioessays. 2011 Nov;33(11):851-9
pubmed: 22006825
Chem Biol. 2012 Dec 21;19(12):1515-24
pubmed: 23261596
Cell Mol Life Sci. 2020 Jul;77(13):2621-2639
pubmed: 31605148
Oncogene. 2011 Sep 8;30(36):3875-86
pubmed: 21460851
J Clin Oncol. 2009 Sep 10;27(26):4352-6
pubmed: 19635999
Int J Oncol. 2019 Feb;54(2):407-419
pubmed: 30570109
J Clin Invest. 2011 Jan;121(1):342-54
pubmed: 21123947
Development. 2005 Aug;132(15):3459-70
pubmed: 16000382
Cell Res. 2013 Dec;23(12):1417-9
pubmed: 24080726
Nat Rev Cancer. 2017 Jan 27;17(2):93-115
pubmed: 28127048
Ann Oncol. 2014 Oct;25(10):1889-1900
pubmed: 24718888
Oncogene. 2013 Apr 11;32(15):1921-32
pubmed: 22665065
Nat Genet. 2014 Oct;46(10):1097-102
pubmed: 25151357
Genes Cancer. 2010 Jul;1(7):700-7
pubmed: 21103004
Gastroenterology. 2019 Jan;156(1):187-202.e14
pubmed: 30267710
Anticancer Drugs. 2015 Mar;26(3):272-83
pubmed: 25486598
Nat Neurosci. 2010 Nov;13(11):1365-72
pubmed: 20935640
J Biol Chem. 2011 Apr 15;286(15):13754-64
pubmed: 21349854
Mol Cell Pharmacol. 2014;6(3):228
pubmed: 25745537
Cell Death Dis. 2013 Aug 08;4:e759
pubmed: 23928698
Cell. 2003 Jan 24;112(2):243-56
pubmed: 12553912
J Exp Med. 2011 Feb 14;208(2):295-312
pubmed: 21282377
Mol Cancer Res. 2016 Nov;14(11):1097-1109
pubmed: 27470268
Leukemia. 2014 Dec;28(12):2324-35
pubmed: 24727676
Nat Immunol. 2013 May;14(5):470-9
pubmed: 23542741
Nat Rev Cancer. 2008 Feb;8(2):83-93
pubmed: 18094723
Oncotarget. 2015 Jun 30;6(18):16559-72
pubmed: 26041884
Leukemia. 2010 Dec;24(12):2005-13
pubmed: 20944675
Mol Cell. 2017 Nov 16;68(4):645-658.e5
pubmed: 29149593
Annu Rev Cell Dev Biol. 1999;15:435-67
pubmed: 10611969
Cell. 2013 Aug 1;154(3):556-68
pubmed: 23911321
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2776-8
pubmed: 9096291
World J Gastrointest Oncol. 2014 May 15;6(5):112-20
pubmed: 24834141
J Cell Sci. 2011 Jan 1;124(Pt 1):100-12
pubmed: 21147854
Lung Cancer. 2018 Jul;121:41-47
pubmed: 29858025
Natl J Maxillofac Surg. 2016 Jan-Jun;7(1):17-20
pubmed: 28163473
J Pediatr Hematol Oncol. 2015 Jan;37(1):e23-30
pubmed: 25493453
Biochim Biophys Acta. 2010 Dec;1806(2):258-67
pubmed: 20600632
Mol Cancer. 2018 Aug 7;17(1):115
pubmed: 30086763
J Natl Cancer Inst. 2014 May 16;106(6):dju107
pubmed: 24838835
Biosci Rep. 2020 Apr 30;40(4):
pubmed: 32239181
Methods Mol Biol. 2010;596:47-76
pubmed: 19949920
Nature. 2011 Mar 3;471(7336):104-9
pubmed: 21368833
Oncol Rep. 2018 Apr;39(4):1910-1918
pubmed: 29436678
Oncotarget. 2014 Apr 30;5(8):2000-15
pubmed: 24899581
Cancers (Basel). 2019 Feb 19;11(2):
pubmed: 30791487
Pediatr Blood Cancer. 2014 Mar;61(3):424-30
pubmed: 24424791
Cold Spring Harb Perspect Biol. 2009 Nov;1(5):a001883
pubmed: 20066118
Clin Cancer Res. 2010 Jun 1;16(11):2932-8
pubmed: 20501624
Biomed Pharmacother. 2017 Jun;90:548-554
pubmed: 28407575
Cancers (Basel). 2014 Sep 05;6(3):1769-92
pubmed: 25198391
Endocrinology. 2008 Dec;149(12):5972-83
pubmed: 18719023
Pediatr Blood Cancer. 2014 May;61(5):788-96
pubmed: 24249312
J Pathol. 2012 Jan;226(2):352-64
pubmed: 21990031
Oncol Rep. 2015 Nov;34(5):2215-24
pubmed: 26324296
PLoS Biol. 2013;11(6):e1001586
pubmed: 23776410